Assessment of Time Since Death using Forensic Autopsies based on the Presence of Rigor Mortis– A Cross-Sectional Study

ABSTRACT

Introduction: Sitagliptin is a dipeptidyl-peptidase inhibitor(DPP-4 inhibitor) Like other DPP-4 inhibitors its actionis mediated by increasing levels of the incretin hormonesglucagon-like peptide-1 (GLP-1) and gastric inhibitorypolypeptide (GIP). Sitagliptin is effective in lowering HbA1cand fasting as well as postprandial glucose in monotherapyand in combination with other oral antidiabetic agents. Thestudy was aimed to evaluate the effect of sitagliptin on fastingand postprandial blood sugar, fasting plasma insulin levelsand HbA1C in patients with type-2 Diabetes Mellitus at 0level and after 16 weeks of treatment with sitagliptin.Material and Methods: A prospective study comprising 70diagnosed cases of type 2 diabetes mellitus was carried out.These patients were put on sitagliptin 100 mg OD for 16weeks and venous blood samples were taken at 0 level andafter 16 weeks.Results The decrease in mean fasting plasma glucose levelsat 0 week and 16 weeks was 40.18mg/dl (17.71%) therapy.The change in mean post prandial glucose level was 56.18mg/dl (19.97%). On Statistical analysis, the reduction in meanfasting plasma glucose levels and post prandial blood sugar intotal number of patients was highly significant (p<0.001). Thechange in mean glycosylated hemoglobin level was 0.88%(9.75%)and p value was also highly significant p<0.001.The change in mean plasma insulin level was 2.50μIU/ml(10.69%). The decrease in values in study group at 4 monthswas statistically highly significant.Conclusions: The study concludes that Sitagliptin representsa substantial advance in antidiabetic therapy and it helps inimproving the diabetic profile of type 2 diabetes patients.